Recent Updates
Recently added Catalysts

MNOV MN-166 ALS Readout: Phase 3 Watch Aug 17

In the months ahead, we're keeping a close eye on several Phase 2 and Phase 3 trials, especially from MNOV and CMPX. These trials pose both opportunities and risks for investors, with the potential to reshape markets for various conditions, including Amyotrophic Lateral Sclerosis and Biliary Tract Cancer. We’ll look at these clinical trials and their implications for stakeholders.

The full Phase 2 and Phase 3 readouts to watch

Registry primary completionTickerDrugIndicationPhasePoA
2026 (company release)MNOVMN-166, placebo (+0% run-up)Amyotrophic Lateral SclerosisPHASE2n/a
Reported September 2026MNOVMN-001, MN-001 placebo (+0% run-up)Diabetes Mellitus, Type 2PHASE2n/a
Reported April 2025CMPXCTX-009, Paclitaxel (+18.3% run-up)Biliary Tract CancerPHASE2n/a
Q1 2027 (company release)MLTXSonelokimabHidradenitis SuppurativaPHASE3n/a 🔒
Reported August 2026MLTXSonelokimab, PlaceboArthritis, PsoriaticPHASE3n/a 🔒
H2 2027 (company)ALTPemvidutide, PlaceboAlcohol-associated Liver DiseasePHASE2n/a 🔒
2026-11DBVTDBV712 250 mcg, PlaceboAllergyPHASE3n/a 🔒
2029-05MIRMBrelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mgChronic Hepatitis D InfectionPHASE2n/a 🔒
Reported October 2026MIRMMaralixibat, PlaceboCholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)PHASE3n/a 🔒
2030-01CYTKAficamten, PlaceboPediatricPHASE2n/a 🔒
2026-09-30GSKGSK4527226, PlaceboAlzheimer's DiseasePHASE2n/a 🔒

Dates are trial registry primary completion dates, not company guidance.

MNOV's MN-166: The Phase 2 Readout for ALS

MediciNova expects topline results from the Phase 2b/3 COMBAT-ALS trial of MN-166 in Amyotrophic Lateral Sclerosis by the end of 2026. This trial could be significant, given ALS's devastating impact and the unmet needs it presents. MN-166 aims to modify the disease's progression, a challenging feat in clinical trials. Despite this, the market has shown no major movement ahead of the readout, with a 0% run-up, suggesting either cautious optimism or a lack of awareness about the potential impact. Without placebo-controlled data available, MNOV faces pressure to produce compelling results that could justify moving to phase 3 trials.

MNOV's MN-001: A Phase 2 Readout for Type 2 Diabetes

MNOV has since reported topline results from its Phase 2 trial of MN-001 in Type 2 Diabetes (September 2026). Diabetes affects millions globally. The drug works by enhancing insulin sensitivity, crucial for managing blood glucose levels. Similar to MN-166, the stock showed a 0% run-up before this post.

CMPX's CTX-009: Anticipating Phase 2 Readout for Biliary Tract Cancer

CTX-009 (now tovecimig), a treatment for Biliary Tract Cancer, met its primary endpoint of overall response rate in CMPX's Phase 2/3 COMPANION-002 trial in April 2025, and CMPX reported its secondary endpoints in April 2026. This challenging indication has few treatment options. The trial tested CTX-009 plus Paclitaxel against Paclitaxel alone. The stock had an 18.3% run-up before this post.

Upcoming Clinical Trial Results: A Broader Look

Beyond these immediate phase 2 readouts, other trials on the horizon deserve attention. MLTX has since reported Week 52 results for Sonelokimab in Hidradenitis Suppurativa from the Phase 3 VELA program (June 2026). This disease has drawn interest due to its chronic nature and demand for effective treatments. For GSK's GSK4527226 in Alzheimer's Disease, the trial registry lists primary completion in September 2026. These trials could introduce new therapeutic options in often underserved fields.

Market Dynamics and Investor Sentiment

Current market sentiment shows cautious optimism as investors consider the potential of these upcoming phase 2 readouts. The lack of significant stock price increases for some candidates suggests the market might not fully grasp the implications of positive trial results. This scenario could be a chance for keen investors to analyze data and market conditions closely. Approaching these readouts, expect increased volatility, especially for stocks like MNOV and CMPX in high-stakes areas.

The Importance of Monitoring Insider Activity

Insider activity often offers valuable insights into management's confidence regarding upcoming phase 3 readouts. Monitoring these indicators can help investors gauge sentiment and potential movements before key data releases. For instance, increased insider buying ahead of significant trial results may signal confidence in positive outcomes. On the other hand, selling could be a warning sign.

The bottom line

Staying informed and engaged with the data as these critical phase 2 readouts approach will be vital for making astute investment decisions.

Frequently asked questions

What is a phase 3 readout?
A phase 3 readout refers to the results from a late-stage clinical trial that assesses the effectiveness and safety of a treatment in a larger patient population.
What has happened to these Phase 2 trials since?
MNOV reported MN-001 topline results in September 2026, and CMPX's CTX-009 met its primary endpoint in April 2025.
What should investors look for before a phase 3 readout?
Investors should monitor insider trading activity, market sentiment, and any preliminary data that may indicate the potential success of the upcoming trial.
Why is monitoring run-up percentages important?
Monitoring run-up percentages helps investors gauge market expectations and sentiment regarding the potential success of upcoming clinical trial results.